<!DOCTYPE html>
<html lang="ko">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>NEWS Letter</title>
</head>
<body>
    <table width="800" cellpadding="0" cellspacing="0" style="padding:0; border:0 none; margin:0 auto; word-break: keep-all;">
        <tr>
            <td colspan="2">
                <img src="http://sinvi.co.kr/sinvi/newsLetterForm/assets/img/header.jpg" alt="CSI:를 위한 news letter" style="display:block; width:100%;">
            </td>
        </tr>
        <tr>
            <td style="padding:20px; padding-bottom: 10px;" colspan="2">
                <table cellpadding="0" cellspacing="0" style="width:100%;padding:0; border:0 none; margin:0 auto;">
                    <tr>
                        <td style="padding:20px; background:#f5f5f5; text-align: center; font-weight:bold;">
                            Novel cryoballoon ablation system for pulmonary vein isolation<br>
                            : multicenter assessment of efficacy and safety(ANTARCTICA study)</td>
                    </tr>
                </table>
            </td>
        </tr>
        <tr>
            <td style="padding:10px; padding-left:20px; width: 50%;">
                <table cellpadding="0" cellspacing="0" style="width:100%;padding:0; border:0 none; margin:0 auto;">
                    <tr>
                        <td style="padding:20px; background:#f5f5f5; text-align: left;">
                            <strong style="display: block; font-size: 24px; color: #1010ea;">Reason to Read</strong>
                            - The first study reporting on the acute &nbsp;&nbsp;efficacy, mid-term outcome and safety of &nbsp;&nbsp;POLAR x-based PVI in a multi-center study.<br>
                            - This study is prosepective, Multi-center, &nbsp;&nbsp;observational.<br>
                            - A total of 317 patients and 1256 PVs(305 &nbsp;&nbsp;RSPVs, 305 RIPVs, 317 LSPVs, 317 LIPVs, &nbsp;&nbsp;and 12 left common pulmonary veins &nbsp;&nbsp;(LCPVs))
                        </td>
                    </tr>
                </table>
            </td>
            <td style="padding:10px; padding-right:20px; vertical-align: top; width: 50%; position: relative;" rowspan="2">
                <table cellpadding="0" cellspacing="0" style="height: calc(100% - 20px); padding:0; border:0 none; margin:0 auto;position: absolute;top: 10px;left: 10px;bottom:20px; right:20px;">
                    <tr>
                        <td style="padding:20px; background:#f5f5f5; text-align: left; vertical-align: top;">
                            <strong style="display: block; font-size: 24px; color: #1010ea;">Conclusion</strong>
                            - he first reported analysis comparing the &nbsp;&nbsp;Polar X with the AFA showed similar &nbsp;&nbsp;efficacy and safety for both systems.<br>
                            - In this large multicenter assessment, the &nbsp;&nbsp;novel Polar X CB shows a promising &nbsp;&nbsp;efficacy and safety profile after a short &nbsp;&nbsp;learning curve.<br>
                            - For the comparison of periprocedural &nbsp;&nbsp;complications for T1 and T2 significant &nbsp;&nbsp;differences were found for serious adverse &nbsp;&nbsp;events (<span style="color:#FF0000;">T1: 9.3%, T2: 3.0%.</span> P = 0.018).
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
        <tr>
            <td style="padding:10px; padding-left:20px; width: 50%;">
                <table cellpadding="0" cellspacing="0" style="width:100%; padding:0; border:0 none; margin:0 auto;">
                    <tr>
                        <td style="padding:20px; background:#f5f5f5; text-align: left;">
                            <strong style="display: block; font-size: 24px; color: #1010ea;">Summary of results</strong>
                            - <strong>Efficacy</strong><br>
                            &nbsp;&nbsp;■ 1252 (<span style="color:#FF0000;">99,7%</span>) PVs were successfully &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;isolated utilizing mainly the short tip &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POLAR X CB (82%).<br>
                            &nbsp;&nbsp;■ Real-time PVI was registered in 72% of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PVs.<br>
                            &nbsp;&nbsp;■ he mean minimal CB temperature was &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="color:#FF0000;">−57.9±7°C.</span><br><br>
                            - <strong>Safety</strong><br>
                            &nbsp;&nbsp;■ The rate of serious adverse events was &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="color:#FF0000;">6.0%</span> which was significantly reduced &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;after a learning curve of 25 cases (<span style="color:#FF0000;">9.3% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vs. 3.0%, P=0.018</span>).<br>
                            &nbsp;&nbsp;■ The rate of recurrence-free was <span style="color:#FF0000;">86.1%</span> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;after mean follow-up of 226±115 days &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;including a 90-day blanking period.
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
        <tr style="background: url('http://sinvi.co.kr/sinvi/newsLetterForm/assets/img/bg.jpg')no-repeat bottom left">
            <td style="padding:20px; padding-top: 10px; ;" colspan="2">
                <table cellpadding="0" cellspacing="0" style="width:100%;padding:0; border:0 none; margin:0 auto;">
                    <tr>
                        <td style="padding:20px; background:#f5f5f5; text-align: left; ">
                            <strong style="display: block; font-size: 24px; color: #1010ea;">Key message for CAS</strong> 
                            - <strong>Learning curve(25case) 이후 procedure time의 감소가 있었으나 통계적으로 유의미한 결과는 &nbsp;&nbsp;아님. </strong><br>
                            &nbsp;&nbsp;: For the comparison of the mean procedure time of the 1st 25 cases vs. the later cases from &nbsp;&nbsp;&nbsp;the 26th patient, a trend towards short duration <span style="color:#FF0000;">but no statistical difference has been observed</span> &nbsp;&nbsp;&nbsp;(T1: 97.1±46 min vs. T2: 87.8±35.4 min, <span style="color:#FF0000;">P=0.635</span>). Similar findings have been detected for &nbsp;&nbsp;&nbsp;fluoroscopy time (T1: 16.4±11 min vs. T2: 13.9±8.6 min, P=0.406).<br><br>
                            - <strong>평균 minimal temperature of CB는 −57.9±7.2°C.로 관련 연구들에 따르면 AFA에 비교하여 더 &nbsp;&nbsp;낮으나 낮게 측정된 명확한 이유는 밝혀지지 않음.</strong><br>
                            &nbsp;&nbsp;: mean Minimal temperature :  −57.9±7.2°C. but, <span style="color:#FF0000;">The reason for this observation is still unknown.</span><br>
                            &nbsp;&nbsp;&nbsp;*minimal CB nadir temperature was significantly lower compared with the AFA-CB <br>
                            &nbsp;&nbsp;&nbsp;A. ICE-AGE-X: −57 ±7°C vs −50±6°C, P=0.0046,<br>
                            &nbsp;&nbsp;&nbsp;B. Moser et al: −60 [−65, −55]°C vs. −48 [−54, −45] °C, P&lt;0.0019,<br>
                            &nbsp;&nbsp;&nbsp;C. Yap et al.: −55°C vs. −47°C, P&lt;0.0015).<br><br>
                            - <strong>Learning curve 이전과 이후의 complications 발생율의 차이가 크며, 평균 6.0%의 수치는 AFA &nbsp;&nbsp;PRO와 비교했을 때 높은 수치이며, 가장 흔한 합병증인 PNI 발생률도 AFA PRO 대비 높음</strong><br>
                            &nbsp;&nbsp;&nbsp;: The rate of serious adverse events <span style="color:#FF0000;">was 6.0%</span> which was significantly reduced after a learning &nbsp;&nbsp;&nbsp;&nbsp;curve of 25 cases (<span style="color:#FF0000;">9.3% vs. 3.0%,</span> P=0.018).  *25 case 보다 적은 경우 : 14 (9.3), 25 case 보다 &nbsp;&nbsp;&nbsp;많은 경우 : 5 (3.0)<br>
                            &nbsp;&nbsp;&nbsp;<strong>A. Adverse Event 비교</strong><br>
                            &nbsp;&nbsp;&nbsp;ANTARTIC(Polar x) : <span style="color:#FF0000;">6.0%</span>(19 of 317) vs STOP AF PAS : <span style="color:#FF0000;">5.8%</span>(20 of 344) <br>
                            &nbsp;&nbsp;&nbsp;<strong> B. PNI(most common complication) (PNI event n수, 발생률 모두 MDT가 낮음)</strong><br>
                            &nbsp;&nbsp;&nbsp;ANTARTIC(Polar X): PNI <span style="color:#FF0000;">13</span> of 317 (<span style="color:#FF0000;">4.1%</span>) vs STOP AF & FIRE AND ICE : PNI <span style="color:#FF0000;">11</span> of 344 <span style="color:#FF0000;">(<span style="color:#FF0000;">3.2%</span>) , <span style="color:#FF0000;">10</span> &nbsp;&nbsp;&nbsp;of 374 (<span style="color:#FF0000;">2.7%</span>)
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
    </table>
</body>
</html>